

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**VOLUNTARY ANNOUNCEMENT
THE ACCEPTANCE BY
CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
OF INVESTIGATIONAL NEW DRUG APPLICATION
FOR HEC-648 INJECTION, A MONOCLONAL ANTIBODY
TARGETING THE G PROTEIN OF NIPAH VIRUS**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (together with its subsidiaries, the “**Group**”) on a voluntary basis.

On 24 February 2026, the Center for Drug Evaluation (“**CDE**”) of the China National Medical Products Administration formally accepted the Group’s Investigational New Drug application for HEC-648 Injection, a monoclonal antibody targeting the G protein of Nipah Virus. Phase I clinical trials are expected to commence in 2026.

I. INTRODUCTION TO NIPAH VIRUS

Nipah Virus (NiV) is a highly lethal negative-sense, single-stranded RNA virus, with a fatality rate ranging from 40% to 75% among infected individuals. It can be transmitted through infected animals such as fruit bats, food contaminated by their saliva, urine, or feces, or through close contact with infected individuals, enabling human-to-human transmission. Currently, Nipah virus is classified as a Biosafety Level 4 pathogen, the highest biosafety category. No specific therapeutic drugs or vaccines have been approved for use.

II. PROGRESS OF ANTIBODY AGAINST NIPAH VIRUS

HEC-648 Injection, the drug accepted by the CDE, is a fully human monoclonal antibody targeting the G protein of Nipah Virus. This drug originates from scientific research achievements at the Wuhan Institute of Virology, Chinese Academy of Sciences. In late 2023, the Group signed a cooperation agreement with the Wuhan Institute of Virology, Chinese Academy of Sciences to develop it into a Class 1 innovative drug. In animal model trials, the drug demonstrated a 100% preventive mortality protection and over 80% therapeutic mortality protection. It is the first and

only Chinese-developed therapeutic drug targeting Nipah Virus to enter the clinical registration phase. As a monoclonal antibody targeting the G protein of Nipah Virus, its precise mechanism of action distinguishes it from traditional antiviral drugs, making it particularly suitable for post-exposure prophylaxis and treatment of Nipah Virus infections.

III. PROJECT SIGNIFICANCE

Guided by its mission of “scientific innovation of new drugs for high-quality of healthy life”, the Group has initiated the development of the antibody against Nipah Virus as a strategic reserve. This initiative not only positions us to address emerging infectious disease prevention and control while upholding industry values, but also represents a critical action to bolster national biosecurity and public health defenses by advancing the “integrated health” strategy, enhancing self-reliance in core pharmaceutical technologies, and strengthening its influence in global public health governance.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
24 February 2026

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.